|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
14
|
|
pubmed:dateCreated |
2010-7-16
|
|
pubmed:abstractText |
Pralatrexate (10-propargyl-10-deazaaminopterin) is an antifolate with improved cellular uptake and retention due to greater affinity for the reduced folate carrier (RFC-1) and folyl-polyglutamyl synthase. Based on the PROPEL data, pralatrexate was the first drug approved for patients with relapsed and refractory peripheral T-cell lymphoma. Bortezomib is a proteasome inhibitor that has shown some activity in patients with T-cell lymphoma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3648-58
|
|
pubmed:meshHeading |
pubmed-meshheading:20501616-Aminopterin,
pubmed-meshheading:20501616-Animals,
pubmed-meshheading:20501616-Apoptosis,
pubmed-meshheading:20501616-Boronic Acids,
pubmed-meshheading:20501616-Caspase 8,
pubmed-meshheading:20501616-Caspase 9,
pubmed-meshheading:20501616-Cell Line, Tumor,
pubmed-meshheading:20501616-Disease Models, Animal,
pubmed-meshheading:20501616-Dose-Response Relationship, Drug,
pubmed-meshheading:20501616-Drug Synergism,
pubmed-meshheading:20501616-Drug Therapy, Combination,
pubmed-meshheading:20501616-Humans,
pubmed-meshheading:20501616-Lymphoma, T-Cell,
pubmed-meshheading:20501616-Mice,
pubmed-meshheading:20501616-Mice, SCID,
pubmed-meshheading:20501616-Neoplasm Transplantation,
pubmed-meshheading:20501616-Pyrazines,
pubmed-meshheading:20501616-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
|
|
pubmed:affiliation |
New York University Cancer Institute, NYU Langone Medical Center, New York, New York 10016, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
